RxDoctor Payments Data

Consuelo Ocampo, MD

Family Medicine · Temecula, CANPI 1952408981

Payments from drug & device makers

$8,244in general payments, 2019–2025

Across 328 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Medtronic$889
  • Amarin Pharma, Inc.$659
  • Lilly USA, LLC$654
  • GSK$540
  • AbbVie$460
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$8,232100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,244 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$139,177
Medicare patients
290
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$102,889
JardianceEmpagliflozin63$62,733
OzempicSemaglutide54$48,886
RybelsusSemaglutide25$38,958
JanuviaSitagliptin Phosphate22$28,349
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$26,821
FarxigaDapagliflozin Propanediol27$23,418
MyrbetriqMirabegron21$17,939
Spiriva RespimatTiotropium Bromide30$17,532
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$15,868
XareltoRivaroxaban20$13,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,488
Diclofenac Sodium51$12,760
DapagliflozinDapagliflozin Propanediol14$12,499
VascepaIcosapent Ethyl19$12,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$102,88992 claims
Novo NordiskOzempic, Rybelsus$200$87,84479 claims
Boehringer IngelheimJardiance, Spiriva Respimat$416$80,26593 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,686$62,35492 claims
GSKAnoro Ellipta, Trelegy Ellipta$540$29,35737 claims
MerckJanuvia$17$28,34922 claims
Astellas Pharma US IncMyrbetriq$36$17,93921 claims
Johnson & JohnsonXarelto$237$13,69820 claims
AbbVieSynthroid$460$2,35642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →